))
Back Bay Life Science Advisors brings you expert insights from our advisors and investment bankers in the world of BioPharma & MedTech. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech executives, physicians, and strategists who excel at guiding global life sciences companies and their investors through complex decisions. Join us for insights generated from in-depth scientific, ...
…
continue reading
1
Key Considerations for a US Healthcare IPO
35:03
35:03
Play later
Play later
Lists
Like
Liked
35:03
In this DNB//Back Bay Healthcare Capital Markets podcast episode, learn about the key considerations, mechanics and timelines of going public on a US exchange. Topics in this podcast include: An overview of the decision-making process through execution for US-based and ex-US healthcare companies thinking about listing in the US Core considerations …
…
continue reading
Guests: Pete Bak and Christian Thienel Length: 27 minutes In this episode of The Life Science Report, Dr. Pete Bak and Back Bay Director, Christian Thienel catch up on the area attracting the most industry interest over the past couple of years: the anti-obesity space. From big players looking to capitalize on the renewed interest in the obesity sp…
…
continue reading
Welcome to another episode with the DNB//Back Bay Partnership for Healthcare. In this episode Jonathan Gertler, Back Bay CEO and Managing Partner, is once again joined by James Cirenza, Head of Fixed Income and Equities at DNB, Kristoffer Braaten, Director of US Equity Capital Markets at DNB, and Vasilios Kofitsas, Managing Director of Investment B…
…
continue reading
1
Vaccine Developments 2024: A Podcast Discussion on Latest Vaccine Technology and Ongoing Clinical Developments
37:34
37:34
Play later
Play later
Lists
Like
Liked
37:34
Guests: Pete Bak and Christian Thienel Length: 37 minutes With the advent of COVID-19 in 2020 and 2021, we saw a tremendous amount of interest in not only COVID vaccines, but other companies riding the tailwind and developing vaccine therapies that span across viral illness, maternal infections and bacterial infections. In this episode resident imm…
…
continue reading
1
Trends and Investment Activity in Radiopharmaceuticals and Psychedelics
25:52
25:52
Play later
Play later
Lists
Like
Liked
25:52
A Podcast Discussion on the Trends and Investment Activity in Radiopharmaceuticals and Psychedelics Guests: Pete Bak and Christian Thienel Length: 25 minutes Here at Back Bay we’ve seen a number of notable trends in the radiopharmaceutical and psychedelic spaces playing out over the past couple of years. Increasingly, investors have been asking our…
…
continue reading
1
Vertex’s Exa-cel to Biogen and Sage’s Zurzuvae: Notable Product Approvals of 2023
25:26
25:26
Play later
Play later
Lists
Like
Liked
25:26
As we move into 2024, Back Bay’s strategic advisors summarize key product approvals from three classes and indications over this past year, including the December CRISPR and Vertex approval of Exa-cel, Biogen and Sage’s August approval of an oral treatment for women with postpartum depression and Genmab and Roche’s May approval in oncology. In this…
…
continue reading
1
Monthly Roundup of News from Healthcare Development
30:04
30:04
Play later
Play later
Lists
Like
Liked
30:04
In our latest podcast, Back Bay Life Science Advisors focused on the chronic and rare disease development of kidney disease. Recently, there have been some changes in treatment, some recent commercial launches and certainly some interest from pharma consolidators, as M&A activity picks up in this area. In this next installment of The Life Science R…
…
continue reading
1
The Current and Future Landscape of Healthcare IPO Markets
23:41
23:41
Play later
Play later
Lists
Like
Liked
23:41
With the DNB//Back Bay Partnership for Healthcare In the current markets, Healthcare continues to rally as the second-largest industry behind technology in the stock market, and in the US markets there’s been roughly $2.5B raised from an IPO standpoint YTD. In Europe, the markets have been more challenging, with IPOs for five companies going public…
…
continue reading
1
The Heart of the Matter: Behind the Renewed Interest in Cardiovascular Disease
24:43
24:43
Play later
Play later
Lists
Like
Liked
24:43
A conversation on the rising trends in the cardiology space Cardiology has historically been a cornerstone of large pharmaceutical portfolios. The late 2000s and 2010s saw many pharmaceutical companies and investors abandon or severely deprioritize cardiology research and development in favor of oncology, immunology, and neurology. During this epis…
…
continue reading
1
The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates
25:54
25:54
Play later
Play later
Lists
Like
Liked
25:54
In this episode, Dr. Peter Bak is joined by Trent Gordon and Dr. Mavra Nasir as they discuss their Bioprocess Online article published earlier this year, “The Transactional Landscape of ADCs: A Payday for Payloads.” This conversation explores the dynamics and data within the emerging ADC field, including: Background information on the class of ther…
…
continue reading
1
Investing in Health Tech & Digital Medicine: Expert Talk with Mikaela Odlander & Edward Kliphuis
29:03
29:03
Play later
Play later
Lists
Like
Liked
29:03
The world of health tech has changed dramatically since decades ago when physicians had to endure 11 keystrokes to prescribe a single aspirin. These days, AI-based radiology and AI-based pathology are transforming patient lives through machine learning and data analytics, in some cases offering early disease warning systems and improving quality of…
…
continue reading
1
Contingencies for Biopharma, Medtech Deal Planning in a Down Market
28:35
28:35
Play later
Play later
Lists
Like
Liked
28:35
For biopharma and medtech companies developing new treatments, capital for advancement and growth is invariably dependent on strategic preparation, differentiation, and persistence. Good preparation can mean funding or famine in a retracted market—and ultimately can impact the trajectory of a company and whether treatment reaches people in the clin…
…
continue reading
1
Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022
37:16
37:16
Play later
Play later
Lists
Like
Liked
37:16
In our first podcast episode of 2023, Back Bay’s strategic advisors summarize some of the most compelling healthcare development stories from 2022. From CRISPR and gene editing advancement to cross-species organ transplantation and the latest in the evolving regulatory and reimbursement landscape, these stories captivated us and continue to herald …
…
continue reading
1
Preparing BioPharma and Medtech Companies for Public Listing - Back Bay Life Science Advisors and Nasdaq Nordic
28:01
28:01
Play later
Play later
Lists
Like
Liked
28:01
For biopharma and medtech companies, the decision to go public is predicated on many business decisions—what kind of capital can be raised? Is our investor base strong and interested? Is now the right time? The Nordic Markets offer some distinct advantages at the earlier stage, and also offer new possibilities for US companies to list abroad. And a…
…
continue reading
1
The Promising Field of Targeted Protein Degraders (TPDs)
23:10
23:10
Play later
Play later
Lists
Like
Liked
23:10
with Back Bay Life Science Advisors’ Dr. Peter Bak and Dr. Mavra Nasir Dr. Mavra Nasir recently published a thought piece in Biopharma Dealmakers outlining the current state of play in the promising field of protein degradation. In this episode, Dr. Nasir sits down with Peter Bak to discuss the recent surge of venture funding and partnerships surro…
…
continue reading
1
Early Market Access and Pricing with Pete Bak, Christian Thieniel and Brendan Wang
29:44
29:44
Play later
Play later
Lists
Like
Liked
29:44
This is the first episode in our podcast series of Q&As on biopharma and medtech development—directly from active developers. Our podcast listeners, including Back Bay clients, have submitted timely and relevant questions about life science development and the daily challenges they face. Christian Thieniel and Brendan Wang, two senior members of th…
…
continue reading
1
Living Medicines – Current and Future Uses of Car T Cells with Peter Bak, PhD and Mike Bogetofte Barnkob, MD, PhD
29:42
29:42
Play later
Play later
Lists
Like
Liked
29:42
In this episode of Back Bay’s industry podcast, The Life Science Report, Dr. Peter Bak is joined by Mike Bogetofte Barnkob, a doctor with the Department of Clinical Immunology at Odense University Hospital in Denmark and a research fellow at the University of Southern Denmark, to discuss current perspectives—clinical, scientific and manufacturing—o…
…
continue reading
1
The Evolving Regulatory Framework for Novel Medicines in the EU
25:53
25:53
Play later
Play later
Lists
Like
Liked
25:53
Biopharma companies looking to establish a footprint in Europe face country-specific decision-making processes. The health technology assessments (HTAs) in France and Germany, for example, look very different. Does this regional level of thinking make it easier or potentially more difficult to get medicines to market and into the hands of patients …
…
continue reading
1
The Commercial Potential of Optogenetic Therapies
23:14
23:14
Play later
Play later
Lists
Like
Liked
23:14
Fifteen years ago, scientists discovered optogenetics, a technique of using light to stimulate light-sensitive receptors in order to turn brain cells “on” and “off" at the flip of a switch. Advances in optogenetics have allowed this technology to move from the laboratory to humans, and more recently biopharma companies have been quick to incorporat…
…
continue reading
1
The Latest on Antibiotic Development, Back Bay Life Science Advisors with Antabio
22:12
22:12
Play later
Play later
Lists
Like
Liked
22:12
Antibiotics act as a safety net for all of healthcare. They make medical procedures such as surgeries, childbirth and cancer treatments possible, but what happens when bacteria or other microorganisms become resistant to the drugs we use against them? Back Bay Life Science Advisors’ Managing Director Peter Bak sits down with Marc Lemonnier, a molec…
…
continue reading
1
Best Practices for Successful Sell-Side Licensing, Partnering and M&A
25:51
25:51
Play later
Play later
Lists
Like
Liked
25:51
Despite the heavy influx of capital over the past years, medtech or biopharma sell-side assignments can still be ripe with challenges. In this episode of Back Bay’s industry podcast, Back Bay Life Science Advisors’ investment banking team discuss best practices for successful sell-side licensing, partnering, and M&A, including: Best practices for r…
…
continue reading
Cell and gene therapies are currently among the hottest investments in the biotech space, both in the public and private markets. In this episode, Back Bay’s Managing Director and host Pete Bak, PhD is joined by Kyle O’Neil and Brendan Wang, who are returning to the podcast after attending the 2021 Cell and Gene Meeting on the Mesa. Tune in to hear…
…
continue reading
1
MedTech Investing with Paul LaViolette of SV Health Investors and Jonathan P. Gertler, MD, Back Bay Life Science Advisors and BioVentures Medtech Funds
26:33
26:33
Play later
Play later
Lists
Like
Liked
26:33
“I have a deep belief that medtech and healthtech are going to carry us forward to markedly improve delivery and quality of healthcare.” - Jonathan P. Gertler, MD For years, biotech has been the dominant theme in life sciences development, offering a great deal in treatment advances and in terms of investing versatility and returns potential. But w…
…
continue reading
One of the unexpected outcomes of the COVID-19 pandemic has been the rapid and widespread uptake of remote patient monitoring. Just ahead of the pandemic, investment in patient monitoring was booming; priming the system for quick uptake and innovation. As with vaccines, much groundwork had been done to prepare for dramatic innovation and widespread…
…
continue reading
In this episode of our life science industry podcast, Dr. Peter Bak sits down with Brendan Wang and Christian Thienel of Back Bay Life Science Advisors to discuss how pharmaceutical companies price their drugs. They cover the ins and outs of health economics, how payers make sense of a high price, and ways this varies around the globe. With a focus…
…
continue reading
1
The Question of Investment in Antimicrobials
25:25
25:25
Play later
Play later
Lists
Like
Liked
25:25
In this episode Jonathan Gertler, Back Bay’s CEO and Managing Partner, sits down with Dr. Peter Bak, Managing Director at Back Bay, to discuss Dr. Bak’s latest article in STAT News and to talk about the world of anti-infectives. Dr. Bak has more than ten years of expertise in infection and treatment. He began his research at Dartmouth Medical Schoo…
…
continue reading
1
Life Science SPACs: A Forward Look at this Evolving Asset Class
25:17
25:17
Play later
Play later
Lists
Like
Liked
25:17
Welcome to Episode #2 of The Life Science Report. In this week’s episode Jonathan Gertler, Back Bay’s CEO and Managing Partner, is joined by Gregory Benning and Vasilios Kofitsas of Back Bay’s investment banking team to talk about the market of Special Purpose Acquisition Companies (SPACs). The feeling surrounding healthcare SPACs right now is almo…
…
continue reading
1
Gene Therapies: What’s to Come as The Industry Moves Forward
21:52
21:52
Play later
Play later
Lists
Like
Liked
21:52
Welcome to Episode 1 of The Life Science Report. In this episode our host, Dr. Peter Bak, sits down with Brendan Wang and Kyle O’Neil of Back Bay Life Science Advisors to discuss the field of gene therapies and insights from their recently authored piece in Cell & Gene, “The Next Decade In Gene Therapy Innovation — 6 Critical Questions (And Answers…
…
continue reading
